Until last year, for Wall Street, the Onyx Pharmaceuticals Inc. story was all about Nexavar (sorafenib), the drug that Onyx partnered with Bayer AG in 1994. [See Deal] FDA approved Nexavar for advanced kidney cancer in 2005 and for unresectable liver cancer in 2007.
The drug is clearly a blockbuster, with more than $1 billion in total sales globally in 2012. Onyx revenue from the Nexavar collaboration was $288 million. After accounting for foreign...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?